A Scotland, UK microbiome company has reported positive Phase 2a results for an experimental therapy for irritable bowel syndrome (IBS), a functional gastrointestinal disorder. These disorders are related to problems with how the brain and gut work together to maintain gut equilibrium. EnteroBiotix is developing an oral microbiome therapeutic for patients with constipation or diarrhoea, two of the three IBS types. It also has a product in development for liver cirrhosis. In the Phase 2a IBS study, the therapy, EBX-102-02, delivered improvements in symptom severity compared with placebo and sustained this benefit through week seven of treatment. The results were announced on 8 January.
According to the company, the benefits were observed across key parameters including abdominal pain, bowel habit, and quality of life. Importantly, these improvements were observed in both IBC subtypes, constipation and diarrhoea., EnteroBiotix is expected advance the product to Phase 2b.
The trial was supported by the Functional Gut Clinic, a UK gastrointestinal physiology clinic that provides services to public and private institutions across the country. EnteroBiotix was founded in 2017 by James Mallroy, a medical doctor, and initially raised £47 million to build a platform and generate data for its products. EBX-102-02 is a pill composed of a diverse range of microorganisms designed to repopulate and balance the gut.
Copyright 2026 Evernow Publishing Ltd